French Validation of the Recovery Assessment Scale (RAS-FR)
VAL-RAS-FR
Cross-Cultural Adaptation, French Validation, and Development of Derived Versions of the Recovery Assessment Scale (RAS) for the Assessment of Subjective Recovery in Mental Health
2 other identifiers
observational
260
1 country
1
Brief Summary
The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2026
CompletedFirst Submitted
Initial submission to the registry
June 16, 2026
CompletedFirst Posted
Study publicly available on registry
June 25, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2027
June 25, 2026
June 1, 2026
7 months
June 16, 2026
June 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability
The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.
Baseline and 1 month
Secondary Outcomes (3)
Correlation between Recovery Assessment Scale - French Version (RAS-FR) and WHOQOL-BREF (World Health Organization Quality of Life - Brief Version) scores
Baseline
Existential dimension of recovery (RAS-FR-EX) composite score
Baseline
Development of a short-form Recovery Assessment Scale - French Version (RAS-FR-SF)
Baseline
Study Arms (1)
Adult psychiatric patients
Adult psychiatric patients receiving care at EPSM Metz-Jury (inpatient units, day hospital, community mental health centers \[CMP\], and intensive home-based psychiatric care services \[EPSIAD\]) who are able to complete self-report questionnaires in French.
Interventions
Participants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved.
Eligibility Criteria
Adult psychiatric patients receiving care at EPSM Metz-Jury in inpatient units, day hospital settings, community mental health centers (CMP), or through intensive home-based psychiatric care services (EPSIAD). Participants are French-speaking adults able to complete self-report questionnaires independently or with assistance if needed. Patients under legal protection measures may participate in accordance with applicable regulations.
You may qualify if:
- Adult patient (18 years or older)
- Receiving psychiatric care at EPSM Metz-Jury (inpatient unit, day hospital, community mental health center \[CMP\], or intensive home-based psychiatric care service \[EPSIAD\]/post-EPSIAD follow-up)
- Able to understand French
- Able to complete a self-report questionnaire independently or with assistance if needed
- Patients under legal protection measures (guardianship or curatorship) may participate with the agreement of their legal representative, when applicable
You may not qualify if:
- Major cognitive impairment
- Severe clinical condition preventing questionnaire completion or understanding of French
- Refusal to participate
- Prisoner or person deprived of liberty by judicial or administrative decision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
EPSM Metz-Jury
Jury, Moselle, 57245, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Audrey WILLIG, Psychologist
Clinical Research Unit (URC), EPSM Metz-Jury
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 16, 2026
First Posted
June 25, 2026
Study Start
June 1, 2026
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
September 1, 2027
Last Updated
June 25, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be made publicly available. Access to study data may be considered on a case-by-case basis upon request to the sponsor, subject to regulatory requirements, confidentiality obligations, and GDPR compliance.